The methodology is flawed by several factors.
The inclusion/exclusion criteria are not defined well.
Did the Authors exclude from the analyses participants with acute inflammatory disease, since in that cases hs-CRP is not applicable for the risk estimation? This should be clearly stated in the Methods section.
Besides hs-CRP, the Authors should also explain the methods for determining of several other biochemical parameters that were mentioned (i.e. glucose, lipid parameters).
Beside mentioned anthropometric indices, the authors should also describe how they measured waist circumference.
In sub-section entitled "Definition of comorbidities" for each commorbidity the reference is needed.
The Friedewald formula should be explained and needs reference. Also, this part should be moved in previous section, when describing the methods for determining of other biochemical parameters.
Although the Authors reported that they were "unable to assess medications such as non-steroidal anti-inflammatory drugs or corticosteroid that could affect the level of CRP" (page 19, lines 18-22), they should provide the data of usage antihypertensive, lipid-lowering and oral hypoglycemic agents, as well as insulin for each participant. They should also include these data in statistical analysis in order to evaluate the medications effect as confounding variable when examining the relationship between hs-CRP levels and comorbidities. The Authors should provide these data, otherwise they could not classify participants with hypertension, dyslipidemia, metabolic syndrome and diabetes, as it was one of the criteria that was described in sub-section "Definition of comorbidities."
The Authors are suggested to specify the term "thyroid disease", since it is too broad. Page 8, Lines 50-60: The sentence should be rephrased and rewritten more clear. Page 11, line 3 and Page 15, line 58, Page 17, line 22, page 18, line 6: ..."after adjustment"...needs to be added ... for confounding variables. This is also needed in the title of Table 4 . The title of the Table 1 should be changed into "Demographic, clinical and laboratory characteristics" of study population. Also, in Table 1 the levels (and units) of fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides should be added, as well as the number of participants that used antihypertensive, lipid-lowering and hypoglycemic agents. Tables 2 and 3 should be more specified. Discussion section Page 16, lines 6-10: "In the U.S. National Health and Nutrition Examination Survey (NHANES) that includes 21,004 participants, mean CRP was 4.3 ± 7.7 mg/L, and median was 2.1 mg/L (IQR 0.8-4.7)". The mentioned statement needs reference. Page 16, lines 29 and 41: Abreviations A1c and Syk tyrosine kinase should be explained. Page 17, line 52: The sentence should be re-written to be more clear.
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GENERAL COMMENTS
The manuscript was aimed to detect the hs-CRP as a marker for metabolic syndrome from the Korean National Health and Nutrition Examination Survey. This manuscript is well-written. The rationales of the present study are reasonable and interesting. However, there some criticisms may rise and need further clarification.
Major comments: -As hs-CRP is a strong predictor for metabolic syndrome, I suggest authors should further define the level of CRP using ROC curve to define a cut-off point of hs-CRP for dyslipidemia, diabetes, or metabolic syndrome. Please provide this data in the results section. -I also suggest that authors could try to define a lower inflammation and a higher inflammation base on the hs-CRP level, then to compare the prevalence for cardiovascular disease, metabolic syndrome, and the comorbidities, or cancer. Please provide this data in the results section. -Why the authors only detected hs-CRP as an inflammatory marker, not IL-6 or other cytokines? IL-6 also widely used clinically. Please discuss it. -Having a lower BMI may be the reason why Koreans have lower CRP concentrations than in other countries. Is it only for this reason? Is it possible to be related to human genes? Please discuss this. -In Tale 3, why the subjects with allergic rhinitis had a higher hs-CRP level? Please explain this.
-
The components of metabolic syndrome can be directly measured by fasting glucose, lipid profiles, blood pressure, and waist circumference clinically. What is the role of hs-CRP in metabolic syndrome? Does the author want to incorporate hs-CRP into the metabolic syndrome diagnostic factor? Please discuss this.
Minor comments: -Please provide the information with regard to the prevalence of cardiovascular disease, metabolic syndrome, and the comorbidities, or cancer in the Korean in the Introduction section. It may point to the importance of incorporating sensitive biochemical indicators such as hs-CRP into early diagnosis. -In Table 5 , blood pressure did not correlate with hs-CRP, please delete the description of this data in the results section, page 10, line 25 (….SBP, and DBP were positively associated with log hs-CRP).
VERSION 1 -AUTHOR RESPONSE
# Reviewer 1 In this study the Authors aimed to evaluate the association between plasma hs-CRP levels and comorbidities in the Korean adult population using a nationwide survey. Accordingly, they found that hs-CRP was associated with increased risk of dyslipidemia, diabetes, and metabolic syndrome in the general population. Although this issue is well explored, it has not been thoroughly investigated in the Korean population and deserves attention. However, there are some questions that need clarification.
C1. English revision throughout the manuscript is strongly recommended.
R1. Thank you for your comment. Our manuscript was reviewed by a commercial English-language editing service (Editage Editing Services).
C2. The objective of the study should be rephrased in Abstract section.
R2. The objective of the study was clarified in the Abstract section (Page 3, lines 4-5).
C3. The abbreviations should be explained in full when first used in the text. Also, hs-CRP should be uniform throughout the Abstract and Manuscript, since the Authors used both, hs-CRP and CRP.
R3. We have ensured all abbreviations are shown in full at first mention. We have also uniformly used "CRP" instead of "hs-CRP" throughout the manuscript. We have described this in the Materials and Methods section (Page 8, Lines 7-8) as follows: "Plasma high sensitivity-CRP (subsequently referred to as CRP throughout the manuscript)…" C4. When reporting mean age in the Abstract and Manuscript, the Authors need to add "years" (Page 3, lines 23 and 33; Page 6, line 42; Page 10, line 3, as well as in Table 1 ), as well as ±SD in Abstract section and on page10, line 3.
R4. Thank you for your comment. We have corrected this in the revised manuscript.
C5. Page 3, line 32, Page 15, line 60, as well as in Table 1 : Since the Authors reported that hs-CRP was "markedly skewed", mean hs-CRP level of the study population should be replaced with median hs-CRP concentration (interquartile range IQR), rather than presented both. R5. Thank you for your comment. We have used "median CRP concentration" rather than "mean CRP" in the revised manuscript (Page 3, Linew 12-13; Page 21, Lines 6-7). We have presented both median and mean CRP levels in Table 1. C6. Materials and Methods section The methodology is flawed by several factors. The inclusion/exclusion criteria are not defined well. Did the Authors exclude from the analyses participants with acute inflammatory disease, since in that cases hs-CRP is not applicable for the risk estimation? This should be clearly stated in the Methods section.
R6. We excluded participants who were younger than 19 years and participants with missing data. We could not exclude participants with acute inflammatory disease such as acute viral or bacterial infection because there was no data about acute inflammatory conditions in this survey. This is a limitation of this survey. We have mentioned this limitation in the Discussion session of the revised manuscript (Page 25, Lines 21-24; Page 26, Line 1).
C7. Besides hs-CRP, the Authors should also explain the methods for determining of several other biochemical parameters that were mentioned (i.e. glucose, lipid parameters).
R7. We have added the methods for determining levels of total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and glucose to the revised manuscript (Page 8, Lines 10-16).
C8. Beside mentioned anthropometric indices, the authors should also describe how they measured waist circumference. R8. We have included the following statement in the revised manuscript: "For measurement of waist circumference, participants were asked to breathe out, and the waist girth at the mid-point between the lower margin of the ribs and the iliac crest was measured to the nearest 0.1 cm using the Seca 200 (Seca, Hamburg, Germany)." (Page 8, Lines 21-23).
C9. In sub-section entitled "Definition of comorbidities" for each commorbidity the reference is needed.
R9. Definitions of hypertension, prehypertension, diabetes, impaired fasting glucose, hypercholesterolemia, and hypertriglyceridemia were taken from the KNHANES (Page 9, Lines 2-3).
C10. The Friedewald formula should be explained and needs reference. Also, this part should be moved in previous section, when describing the methods for determining of other biochemical parameters.
R10. LDL cholesterol level was calculated using the Friedewald formula (LDL-C = total cholesterol -HDL cholesterol -[triglyceride/5]). We have explained this in the revised manuscript (Page 8, Lines 15-16).
C11. Although the Authors reported that they were "unable to assess medications such as nonsteroidal anti-inflammatory drugs or corticosteroid that could affect the level of CRP" (page 19, lines 18-22), they should provide the data of usage antihypertensive, lipid-lowering and oral hypoglycemic agents, as well as insulin for each participant. They should also include these data in statistical analysis in order to evaluate the medications effect as confounding variable when examining the relationship between hs-CRP levels and comorbidities. The Authors should provide these data, otherwise they could not classify participants with hypertension, dyslipidemia, metabolic syndrome and diabetes, as it was one of the criteria that was described in sub-section "Definition of comorbidities." R11. We discussed this with the statistical team. In the KNAHES data, information about the use of specific medications was only provided for anti-hypertensive agents, lipid lowering agents, oral hyperglycemic agents, and insulin. There was no data about other drugs, such as glucocorticoids, NSAIDs, or other drugs, for the treatment of specific diseases. The KNHANES dataset classified and defined hypertension, diabetes, hypertriglyceridemia, and hypercholesterolemia. We have described these definitions in the manuscript.
"Hypertension was defined as a mean systolic BP (SBP) ≥140 mmHg or diastolic BP (DBP) ≥90 mmHg or the use of antihypertensive agents. Pre-hypertension was defined as an average SBP of 120-139 mmHg or a DBP of 80-89 mmHg. Diabetes mellitus was defined as a fasting plasma glucose ≥126 mg/dL and/or current use of anti-diabetic drugs or insulin due to a previous diagnosis of diabetes. Impaired fasting glucose was defined by a range of fasting plasma glucose levels of 100 mg/dL to <126 mg/dL. Diagnosis of hypercholesterolemia was defined as a total plasma cholesterol level of ≥240 mg/dL after 8 hours of fasting or current use of cholesterol-lowering agents. Hypertriglyceridemia was defined as a triglyceride level of >200 mg/dL after 12 hours of fasting. " (Page 9, Lines 4-12).
Usage of medication is included in the definitions for hypertension, dyslipidemia, and diabetes (outcome variables), so it was not appropriate to adjust for medication as an independent variable.
In addition, the definition of metabolic syndrome was defined according to the modified National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) definition.
"Current ATP III criteria define metabolic syndrome as the presence of any three of the following five traits: (1) central obesity (waist circumference ≥90 cm in Asian men or ≥80 cm in Asian women), (2) hypertriglyceridemia (fasting serum triglycerides ≥150 mg/dL or drug treatment for elevated triglycerides), (3) decreased high-density lipoprotein (HDL) cholesterol (serum HDL cholesterol <40 mg/dL in men and <50 mg/dL in women or drug treatment for low HDL cholesterol), (4) elevated BP (SBP ≥130 mmHg and/or DBP ≥85 mmHg or drug treatment for elevated BP), and (5) hyperglycemia (fasting plasma glucose ≥100 mg/dL or drug treatment for elevated blood glucose) " (Page 9, Lines 14-21).
In the process of reviewing the results with the statistical team, we found that a mistake was made in the exclusion of participants taking medications in the process of classification of metabolic syndrome. Therefore, we reanalyzed metabolic syndrome and have provided reanalyzed data in the revised manuscript (Tables 2, 4 , and 5). Although there was a slight difference in the number of patients with metabolic syndrome, there was no change in the statistical results.
In the same context, the use of medication is included in the definition of metabolic syndrome, so it was not appropriate to adjust for medication as an independent variable. C12. The Authors are suggested to specify the term "thyroid disease", since it is too broad.
R12. Unfortunately, a definition of thyroid disease was not specified in this survey. There was only a differentiation between "thyroid disease" and "thyroid cancer" in KNHANES.
C13. Page 8, Lines 50-60: The sentence should be rephrased and re-written more clear.
R13. As per your comment, we have re-written this sentence in the revised manuscript as follows:
Stroke was defined in the questionnaire as "stroke diagnosed by a physician" through a standardized interview. We asked "Was your stroke diagnosed by a physician?" and there were three possible responses ("Yes", "No", and "I have never been sick before"). Participants who chose 1 (Yes) were classified into the stroke group. Each interview was conducted individually by a trained professional investigator. Other comorbidities were defined in the same way as the stroke diagnosis. Information was collected on other comorbidities diagnosed by a physician, including myocardial infarction or angina, osteoarthritis, rheumatoid arthritis, osteoporosis, pulmonary tuberculosis, asthma, thyroid disease, atopic dermatitis, and allergic rhinitis. Information on malignancies diagnosed by a physician, including gastric cancer, breast cancer, cervical cancer, lung cancer, and thyroid cancer, were also collected (Page 9, Lines 21-24, Page 10, Lines 1-7) C14. Page 11, line 3 and Page 15, line 58, Page 17, line 22, page 18, line 6: ..."after adjustment"...needs to be added ... for confounding variables. This is also needed in the title of Table  4. R14. We have corrected this to "after adjustment for age, income, region, education, marital status, smoking, alcohol consumption, BMI, and physical activity" throughout the manuscript.
In Table 4 , confounding variables are listed in the bottom of the table. If we added this to the title, the length of the title would be too long. Therefore, we deleted the phrase "after adjustment" in the title of Table 4. C15. The title of the Table 1 should be changed into "Demographic, clinical and laboratory characteristics" of study population. Also, in Table 1 the levels (and units) of fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides should be added, as well as the number of participants that used antihypertensive, lipid-lowering and hypoglycemic agents.
R15. We have corrected the title. We have also added laboratory parameters and the number of participants who used antihypertensive, lipid lowering, and hypoglycemic agents in the revised manuscript in Table 1. C16. The title of the Tables 2 and 3 should be more specified. Tables 2 and 3 R19. Thank you for your comment. This sentence has been deleted because it was considered unnecessary. The detailed contents are described from the following sentence.
R16. We have edited the titles of
# Reviewer 3
Major comments:
C1. As hs-CRP is a strong predictor for metabolic syndrome, I suggest authors should further define the level of CRP using ROC curve to define a cut-off point of hs-CRP for dyslipidemia, diabetes, or metabolic syndrome. Please provide this data in the results section.
R1. We performed ROC curve analysis to evaluate the diagnostic value of serum CRP concentration for metabolic syndrome, hypertriglyceridemia, and diabetes. The maximum value of the Youden`s index was selected as the optimum cut-off point. A CRP concentration cut-off value of more than 0.54 mg/L had 68.5% sensitivity, 56.6% specificity, 48.1% positive predictive value, 75.4% negative predictive value, and 61.0% accuracy for metabolic syndrome. In hypertriglyceridemia, a CRP concentration cut-off value of 0.56 mg/L had 70.8% sensitivity, 51.3% specificity, 20.8% positive predictive value, 90.6% negative predictive value, and 54.3% accuracy. In diabetes, a CRP concentration cut-off value of more than 0.53 mg/L had 67.7% sensitivity, 48.9% specificity, 16.3% positive predictive value, 91.1% negative predictive value, and 51.3% accuracy.
We have added this information to the Results section of the revised manuscript (Page 12, Lines 17-24; Page 13, Line 1).
C2. I also suggest that authors could try to define a lower inflammation and a higher inflammation base on the hs-CRP level, then to compare the prevalence for cardiovascular disease, metabolic syndrome, and the comorbidities, or cancer. Please provide this data in the results section.
R2. Based on the cut-off value for metabolic syndrome from the ROC curve analysis, we defined lower inflammation as a CRP concentration of <0.54 mg/L and higher inflammation as a CRP concentration of ≥0.54 mg/L. The prevalence of stroke, hypercholesterolemia, hypertriglyceridemia, diabetes, impaired fasting glucose, hypertension, prehypertension, metabolic syndrome, osteoarthritis, osteoporosis, and thyroid disease were significantly higher in the higher inflammation group than in the lower inflammation group. We have added these results in the revised manuscript (Page 13, Lines 1-8; Table 6 ).
C3. Why the authors only detected hs-CRP as an inflammatory marker, not IL-6 or other cytokines? IL-6 also widely used clinically. Please discuss it.
R3. Thank you for your comment. In the KNHANES data, IL-6 and other cytokines were not included in the survey. This is a limitation of our study and we have added this limitation to the revised manuscript (Page 26, Lines 2-3).
C4. Having a lower BMI may be the reason why Koreans have lower CRP concentrations than in other countries. Is it only for this reason? Is it possible to be related to human genes? Please discuss this.
R4. Thank you for your comment. We have added information about the influence of genetics on CRP concentration to the revised manuscript as follows:
CRP levels closely correlate with mean BMI at a population level across ethnic groups. However, obesity does not completely explain the CRP levels. Race and gender differences exist in the distribution of CRP. Genome-wide association studies (GWASs) using the women's Health Initiative SNP Health Association Resource reported the ancestry-specific genetic variants associated with CRP concentration. East Asian ancestry was associated with lower age and lower BMI-adjusted CRP compared to African American ancestry. The triggering receptors expressed by the myeloid cells 2 (TREM2) variant associated with higher CRP is common in African American individuals, but is much less common in Asian populations (Page 21, Lines 14-22).
C5. In Tale 3, why the subjects with allergic rhinitis had a higher hs-CRP level? Please explain this.
R5. In Table 3 , subjects with allergic rhinitis had a lower CRP; however, after adjustment for age, sex, income, region, education, marital status, alcohol consumption, body mass index, smoking, and physical activity, there was no statistical significance (Table 4 ).
C6. The components of metabolic syndrome can be directly measured by fasting glucose, lipid profiles, blood pressure, and waist circumference clinically. What is the role of hs-CRP in metabolic syndrome?
Does the author want to incorporate hs-CRP into the metabolic syndrome diagnostic factor? Please discuss this.
R6. Among the components of metabolic syndrome, glucose, lipid profile, and waist circumference were significantly associated with CRP in the current study. The mechanism of proinflammatory status and metabolic syndrome is not yet fully understood. Adipocytes in patients with metabolic syndrome release tumor necrosis factor-α and IL-6 into circulation that stimulate CRP production in the liver and induce insulin resistance. CRP is also released in the adipocytes of body fat and CRP is independently associated with total body fat, central fat, and insulin resistance. Besides, in a genomewide association study on 6,345 healthy women, it was reported that seven loci were associated with plasma CRP levels. Protein products of six of these seven loci are directly involved in metabolic syndrome, insulin resistance, beta cell function, weight homeostasis, and/or premature atherosclerosis. Common variations in several genes involved in metabolic and inflammatory regulation have significant effects on CRP levels.
We analyzed cut-off values for metabolic syndrome, as well as hypertriglyceridemia and diabetes. The CRP cut-off value for metabolic syndrome was 0.54 mg/L with 68.5% sensitivity and 48.1% specificity. The CRP concentration was likely to be low because this was a study of the general population rather than hospitalized patients. The cut-off values for hypertriglyceridemia and diabetes were 0.56 mg/L and 0.53 mg/L, respectively. In hypertriglyceridemia and diabetes, the sensitivity of the cut-off value was about 70% and the specificity was about 50%, which was similar to that of metabolic syndrome. This sensitivity is not very high (70%) and the specificity is low (50%). Therefore, the incorporation of CRP into the diagnostic criteria for metabolic syndrome or cardiovascular risk factors is not suggested, based on the results of the current study. More studies on CRP and other inflammatory markers are needed. However, these results suggest that people with completely normal CRP levels are less likely to have metabolic syndrome, hypertriglyceridemia, and diabetes.
We have added this information to the revised manuscript in the Discussion section (Page 23, Lines 7-16; Page 24, Lines 9-21).
